IN ADULTS AND CHILDREN
Type 2 or 3 SMA (later-onset)
IN INFANTS
Type 1 SMA (infantile-onset)
No one in the clinical studies permanently stopped taking Evrysdi because of side effects of treatment.*
These are not all of the possible side effects of Evrysdi.
For more information on the risk and benefit profile of Evrysdi, ask your healthcare provider or pharmacist.
Ongoing studies are exploring the safety of Evrysdi in individuals who previously received a different SMA treatment.
*As of March 2022.
As always, your doctor is the best resource for any questions. It’s important to talk to your doctor if you notice any changes, begin any new medication, or make changes in your overall care. Below are some tips that may help if you experience these changes.
If you experience diarrhea:
If you experience rash:
†Cases with a known duration.
A neurologist answers the top 5 community questions
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.